Hepatic Insulin Clearance Is the Primary Determinant of Insulin Sensitivity in the Normal Dog

Marilyn Ader, Darko Stefanovski, Stella P. Kim, Joyce M. Richey, Viorica Ionut, Karyn J. Catalano, Katrin Hucking, Martin Ellmerer, Gregg Van Citters, Isabel R. Hsu, Jenny D. Chiu, Orison O. Woolcott, Lisa N. Harrison, Dan Zheng, Maya Lottati, Cathryn M. Kolk, Vahe Mooradian, Justin Dittmann, Sophia Yae, Huiwen Liu, Ana Valeria B. Castro, Morvarid Kabir and Richard N. Bergman

Objective: Insulin resistance is a powerful risk factor for Type 2 diabetes and a constellation of chronic diseases, and is most commonly associated with obesity. We examined if factors other than obesity are more substantial predictors of insulin sensitivity under baseline, nonstimulated conditions.

Methods: Metabolic assessment was performed in healthy dogs ($n = 90$). Whole-body sensitivity from euglycemic clamps ($\text{SI}_{\text{CLAMP}}$) was the primary outcome variable, and was measured independently by IVGTT ($n = 36$). Adiposity was measured by MRI ($n = 90$), and glucose-stimulated insulin response was measured from hyperglycemic clamp or IVGTT ($n = 86$ and $36$, respectively).

Results: $\text{SI}_{\text{CLAMP}}$ was highly variable (5.9-75.9 dl/min per kg per $\mu$U/ml). Despite narrow range of body weight (mean, 28.7 ± 0.3 kg), adiposity varied approximately eight-fold and was inversely correlated with $\text{SI}_{\text{CLAMP}}$ ($P < 0.025$). $\text{SI}_{\text{CLAMP}}$ was negatively associated with fasting insulin, but most strongly associated with insulin clearance. Clearance was the dominant factor associated with sensitivity ($r = 0.53$, $P < 0.00001$), whether calculated from clamp or IVGTT.

Conclusions: These data suggest that insulin clearance contributes substantially to insulin sensitivity, and may be pivotal in understanding the pathogenesis of insulin resistance. We propose the hyperinsulinemia due to reduction in insulin clearance is responsible for insulin resistance secondary to changes in body weight.

Introduction

The widespread increase in prevalence of Type 2 diabetes in the United States and abroad has prompted efforts to identify persons at high risk for the disease in the hopes that early intervention may delay or prevent disease onset. One of the most common diabetes risk factors is insulin resistance. While resistance itself may be a heritable trait (1), obesity can further reduce insulin sensitivity. Yet even among lean subjects with normal glucose tolerance, insulin sensitivity can vary substantially (2), suggesting that other factors may be at play that determine sensitivity under baseline conditions.

In nondiabetic subjects, reduced insulin sensitivity is met with compensatory hyperinsulinemia which overcomes sluggish insulin action and maintains glucose tolerance and normal fasting glycemia. It has generally been thought that hyperinsulinemia was the result of upregulation of pancreatic $\beta$-cell sensitivity to glucose, and subsequent increase in secretion of insulin. However, we and others have shown (3,4) that the hyperinsulinemia characteristic of obesity and insulin resistance reflects the combined effects of increased insulin secretion and decreased metabolic clearance of the hormone, primarily by the liver. However, the reverse dynamic is also plausible, that is, that reduction of insulin clearance is the primary event, which could generate hyperinsulinemia that would negatively feed back on insulin-sensitive tissues, thus generating insulin resistance. It remains unclear which physiologic process is the dominant driver that determines insulin sensitivity, particularly under baseline, overnight fasted conditions.

This study was undertaken to identify the major determinants of insulin sensitivity, using data from a sizable cohort of healthy,
TABLE 1 Outline of specific procedures performed in healthy animals

| References | Total # dogs | MRI  | EGC  | STEP | Clamp | IVGTT |
|------------|--------------|------|------|------|-------|-------|
| (5)        | 26           | 26   | 26   | 26   | -     | -     |
| (6)        | 6            | 6    | 6    | 6    | -     | -     |
| (7)        | 8            | 8    | 8    | 4    | -     | -     |
| (8-10)     | 21           | 21   | 21   | 21   | 8     | -     |
| (11)       | 17           | 17   | 17   | 17   | 17    | -     |
| (12)       | 12           | 12   | 12   | 12   | 11    | -     |
| Total      | 90           | 90   | 90   | 86   | 36    | -     |

mongrel dogs. Our results indicate that insulin clearance is the primary determinant of insulin sensitivity under overnight-fasted conditions. We postulate that reduction in insulin clearance by the liver results in hyperinsulinemia which in turn may be lead to development of insulin resistance in the obese dog model. Thus we suggest that insulin resistance may be secondary, rather than primary in the development of insulin resistance secondary to increased storage of fat.

Methods

Animal Model

Procedures were performed on 90 male mongrel dogs (28.7 ± 0.3 kg; ~1-year-old). Data were pooled from previously published studies (5-12). Baseline data were obtained from overnight-fasted animals over a 2-3-week period, prior to enrollment in any pharmacologic or dietary treatment. All animals underwent MRIs to quantify total and regional adipose mass and a hyperinsulinemic euglycemic clamp (EGC) to assess insulin sensitivity. Subsets of these animals also underwent insulin-modified intravenous glucose tolerance tests (IVGTTs; n = 36) or stepwise hyperglycemic clamps (STEP; n = 86). An outline of the specific procedures performed on each dog is shown in Table 1.

At least 1 week prior to testing, dogs were surgically outfitted with a chronic catheter (n = 49) or sampling port (n = 30) in the jugular vein, advanced into the right atrium for sampling of mixed central venous blood. Blood sampling for remaining dogs (n = 11) was performed using peripheral intracatheters inserted percutaneously into a limb vein. Dogs were individually housed in the vivarium under controlled environmental conditions, and fed a combination of dry chow and canned food to maintain stable body weight. Time interval for feeding varied amongst animals (from 1 hr feeding to ad lib regimens), but all testing was performed after an overnight fast, and we observed no effect of feeding pattern on any measured variable. All procedures were approved by the University of Southern California Institutional Animal Care and Use Committee.

Experimental Procedures

The following procedures were performed after overnight fasting. During all procedures (except MRIs), dogs were fully conscious, resting comfortably in a Pavlov sling, and were given free access to water.

1. MRI: dogs were preanesthetized and sedated. Thirty-one-cm axial abdominal images were obtained using a GE 1.5 Tesla Horizon magnet. Computer MRI images were analyzed by a skilled laboratory technician who was blinded to other measures of body composition of index animals. Analysis was performed using Scion Image software, which quantified fat tissue (pixel value: 0-120) and non-fat tissue (pixel value: 121-256) in each slice. Total trunk fat volume was estimated as the integrated fat across all 30 slices. Visceral fat was defined as fat within the peritoneal cavity at ±5 image “slices” from the level where the left renal artery branches from the abdominal aorta (i.e., from 11-cm abdominal range). Adiposity was expressed in units of cm³.

2. Euglycemic hyperinsulinemic clamps: on the morning of the clamp, two intracatheters were inserted percutaneously in each saphenous vein for infusions of glucose and HPLC-purified 3-3H-glucose (tracer). At t = -180 min, a primed infusion of tracer (25 μCi + 0.25 μCi/min; Perkin-Elmer NEN) was initiated, and tracer continued for a 90 min equilibration period. After basal blood sampling, somatostatin (1 μg/min per kg; Bachem) was infused to suppress endogenous insulin secretion. A single step of hyperinsulinemia was induced by systemic insulin infusion (regular purified pork; Lilly) from t = 0-180 min, using one of the following rates: 0.75 mU/min per kg (n = 41), 1.15 mU/min per kg (n = 43), or 1.50 mU/min per kg (n = 6). Euglycemia was maintained by variable rate 50% dextrose infusion, spiked with 3-3H-glucose (specific activity: 2.2 μCi/g). Blood samples were drawn every 10 min from t = 10-60 min, every 15 min from t = 75-150 min, and every 10 min from 160 to 180 min, and assayed for glucose, insulin, and tracer.

3. STEP clamp: after basal blood sampling, glucose was clamped at three sequential glycemic levels by exogenous glucose infusion. Target glucose levels were 100 mg/dl (t = 0-59 min), 150 mg/dl (t = 60-149 min), and 200 mg/dl (t = 150-240 min). Samples were assayed for glucose, insulin, and C-peptide.

4. IVGTT: after basal blood sampling, glucose (0.3 g/kg) was injected at time 0 over 30 sec. Blood samples were drawn at t = 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, and 19 min. At t = 20 min, insulin (0.03 U/kg; Lilly) was injected, and followed by blood sampling at t = 22, 23, 24, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 140, 160, and 180 min. Samples were assayed for glucose and insulin.

5. Fasting plasma values: fasting blood samples were collected from a peripheral vein on a weekly basis for all animals, and plasma was assayed for glucose, insulin, and free fatty acids (FFA). Mean of two weekly basal samples was used for subsequent analysis.

Blood Sampling and Assays

Blood samples were collected in lithium and heparin-coated tubes containing EDTA (paraoxan, a lipoprotein lipase inhibitor, was an
Factors Determining Fasting Insulin Sensitivity

(i.e., steady-state minus basal period), and GLUss is the steady state infusion rate and insulin measured during exogenous insulin infusion.

Steele’s equations, modified for use with labeled glucose infusion.

Diprotin A, and quantification was performed using radioimmunoassay (Linco) (7).

Data Analysis and Calculations

Pooled data from multiple studies were used to examine the relationships between insulin sensitivity and key variables of glucose metabolism and body composition. Specifically, we quantified glucose-stimulated insulin release and insulin clearance, and measured total and regional fat mass. Calculations are outlined below:

1. Insulin sensitivity: the primary measure of whole-body insulin sensitivity calculated for all dogs was obtained from the EGC as previously described (14). Whole-body insulin sensitivity (SICLAMP) was defined as follows:

\[
SICLAMP = \frac{\Delta GINF}{\Delta INS \times GLU_{ss}} \tag{1a}
\]

where \( \Delta GINF \) and \( \Delta INS \) are the respective increments in glucose infusion rate and insulin measured during exogenous insulin infusion (i.e., steady-state minus basal period), and \( GLU_{ss} \) is the steady state glucose concentration. After data smoothing (15), rates of glucose uptake (\( R_g \)) and hepatic glucose output (\( HGO \)) were calculated with Steele’s equations, modified for use with labeled glucose infusion (16). Peripheral insulin sensitivity (SIPCLAMP) was defined as:

\[
SIPCLAMP = \frac{\Delta R_g}{\Delta INS \times GLU_{ss}} \tag{1b}
\]

where \( \Delta R_g \) is the change in \( R_g \) from basal to steady state. Finally, hepatic insulin sensitivity was calculated as:

\[
SIHGOCLAMP = \frac{\Delta HGO}{\Delta INS \times GLU_{ss}} \tag{1c}
\]

where \( \Delta HGO \) is the observed change in HGO (basal minus steady state). Rates of glucose infusion, \( R_g \), and HGO were expressed as mg/kg body weight per min for all calculations of clamp-based insulin sensitivity. Given possible variations in body weight among animals, analysis was also performed with data normalized to volume of nonfat tissue obtained from MRIs instead of body weight. Since no difference was observed in statistical strength or conclusions derived from these data, SICLAMP results are presented using body weight normalization only. Steady state was defined as the final 30 min of the clamp procedure (i.e., \( t = 150-180 \) min).

Secondary measurement of insulin sensitivity was obtained from IVGTTs performed in a subset of animals (\( n = 36 \)). Minimal model analysis was performed to obtain the insulin sensitivity index (SI) using MINMOD Millennium (ver. 6.02; (17)).

2. Glucose-stimulated insulin response: Glucose-stimulated insulin response was calculated from STEP clamps (\( n = 86 \)) as the slope of the line relating plasma insulin to glucose concentrations, using the mean of final 20-30 min from each glycemic period for each variable (i.e., 40-60, 120-150, and 210-240 min). Incremental area under the curve (AUC) was calculated by the trapezoidal rule.

In a subset of animals (\( n = 36 \)), we calculated an additional measure of glucose-stimulated insulin response from the IVGTT. The acute insulin response to glucose (AIRG) was calculated as the incremental insulin AUC from 0-10 min after glucose injection.

3. Insulin clearance: three measures of clearance were obtained for this study. The primary measure, available from all animals tested (\( n = 90 \)), was the metabolic clearance rate of insulin from the EGC (MCRCLAMP), calculated as insulin infusion rate (in \( \mu U/min \) per kg) divided by the mean plasma insulin concentration at steady state (in \( \mu U/ml \)). Units of MCRCLAMP are ml/min per kg.

Two additional measures of insulin clearance were obtained from the IVGTT. Fractional insulin clearance was calculated from the decay of plasma insulin after exogenous injection. Insulin from \( t = 20-80 \) min was fit to the following exponential decay curve using WINSAAM software (ver. 3.0.1), as previously described (3):

\[
INS = INS_b + INS_{max} \times e^{-kt} \tag{2}
\]

where \( INS, INS_b, \) and \( INS_{max} \) are the plasma insulin, basal insulin, and peak insulin concentrations (in \( \mu U/ml \)). Parameter \( k \) represents the fractional clearance rate of insulin (FCRINS), expressed in \( \text{min}^{-1} \). Time interval for analysis was chosen to describe full return of insulin to fasting values, while avoiding occasional fluctuations below basal that can be observed at later time points. It is also assumed that endogenous insulin secretion is suppressed by the exogenous injection (18).

Metabolic clearance rate was also calculated from the IVGTT (MCRIV). This parameter, expressed in the same units as the clamp-derived variable (ml/min per kg), is defined as:

\[
MCRIV = \frac{DOSEINS}{AUC_{INS}} \tag{3}
\]

where \( DOSEINS \) is the dose of injected insulin (0.03 U/kg), and \( AUC_{INS} \) is the above-basal insulin AUC from time of injection (\( t = 20 \) min) to infinity.

Statistics

Basic statistics (t-test and ANOVA, with Tukey’s post hoc analysis when overall significance was detected) were performed using MINITAB statistical software (ver. 13.32; State College, PA). Calculated variables were tested for normality using Tukey’s ladder test on STATA statistical software (ver. 10), and optimal transformation methods (if required) were determined. When applicable, tests for significance were performed on transformed data. Since data have been pooled from multiple independently performed studies, analysis included relevant adjustments to correct for study (i.e., “group” effects), for example, effects of insulin infusion rate or duration of
daily feeding period. Data are reported as mean ± SE. When applied to non-normalized data, results are reported as median. Statistical significance was set at \( P < 0.05 \).

**Results**

**Fasting Plasma Values**

After an overnight fast, baseline values were within normal ranges in all dogs, and all were of normal glucose tolerance (\( K_G > 1.0 \) min\(^{-1} \) from IVGTT; (19)). Fasting glucose averaged 93.5 ± 0.7 mg/dl (range: 75-106 mg/dl), with minimal variation among animals (CV = 7%; Table 2). Fasting insulin was also normal (10.6 ± 0.6 \( \mu \)U/ml), but even at baseline, fasting insulin exhibited much greater relative variability than that observed for glucose (range: 3.1-32.4 \( \mu \)U/ml; CV = 52%). Fasting FFA levels averaged 0.61 ± 0.03 mM, and was not significantly correlated with insulin sensitivity or clearance.

**Body Weight and Adiposity**

There was modest variation in body weight amongst animals (range: 20.9-37.4 kg; CV = 11%) (Figure 1B), but this relatively narrow weight range belied great variation in fat distribution patterns. We measured a strikingly wide range of total trunk adiposity (Figure 1A). Adiposity varied over nearly an eight-fold range, from the leanest animal, with 172 cm\(^3\) of fat mass (7.1% of total trunk tissue) to the most obese animal with 1363 cm\(^3\) total fat, or 39.6% of total tissue. In contrast, visceral adipose mass varied to a significantly lesser degree (~8.6-fold), ranging from 103 to 883 cm\(^3\) (4.2-25.6% total trunk tissue, respectively).

**Insulin Sensitivity**

Dogs exhibited a wide range of insulin sensitivity under baseline, overnight fasted conditions. \( \text{SICLAMP} \) averaged 33.5 ± 1.6 dl/min per kg per \( \mu \)U/ml (\( n = 90; \) median = 31.9), but varied nearly 13-fold from most resistant (5.9) to most sensitive (75.9 dl/min per kg per \( \mu \)U/ml) animal. This broad range was reflective of a large range in \( \text{SICLAMP} \) (5.0-74.7 dl/min per kg per \( \mu \)U/ml; median = 25.0). This range of \( \text{SICLAMP} \) was consistent with another index of total insulin sensitivity, that is, the minimal model-derived insulin sensitivity index (\( S_I \)). In the subset of animals undergoing IVGTTs (\( n = 36 \) of 90 dogs), \( S_I \) averaged 4.5 ± 0.4 \( \times 10^{-4} \) min\(^{-1} \) per \( \mu \)U/ml, with a nine-fold range from most resistant to most sensitive (1.1-10.2 \( \times 10^{-4} \) min\(^{-1} \) per \( \mu \)U/ml). We observed strong correlation between \( \text{SICLAMP} \) and \( S_I \) from the minimal model (\( P = 0.001 \)). Consistent with the reported relationship between obesity and insulin resistance, we observed significant inverse associations between \( \text{SICLAMP} \) and total, visceral, and subcutaneous adipose tissue mass, after adjustments for group effects (Table 3; \( P < 0.012, 0.017, \) and 0.025, respectively).

**Predictors of Baseline Insulin Sensitivity**

In addition to the observed relationship between body composition and insulin sensitivity, we examined whether determinants of circulating insulin are predictive of \( \text{SICLAMP} \) assessed in overnight-fasted animals. Fasting insulin exhibited a significant, negative association with \( \text{SICLAMP} \), such that resistance was accompanied by fasting hyperinsulinemia (\( P < 0.00001 \); Figure 2). Since circulating insulin reflects the combined effects of both \( \beta \)-cell secretion and insulin clearance, we explored the impact of each component process to

---

**TABLE 2** Variability of key metabolic variables under baseline conditions

| Parameter                  | \( n \) | Mean ± SE | Minimum | Maximum | Fold range |
|----------------------------|--------|-----------|---------|---------|------------|
| **Fasting plasma values**  |        |           |         |         |            |
| Glucose                    | 90     | 93.5 ± 0.7| 75.4    | 106.0   | 1.4        |
| Insulin                    | 90     | 10.6 ± 0.6| 3.1     | 32.4    | 10.5       |
| FFA                        | 90     | 0.61 ± 0.03| 0.24   | 1.45    | 6.0        |
| **Body composition**       |        |           |         |         |            |
| BW                         | 90     | 28.7 ± 0.3| 20.9    | 37.4    | 1.8        |
| Total fat                  | 90     | 600 ± 25  | 172     | 1383    | 7.9        |
| Visc fat                   | 90     | 368 ± 15  | 103     | 883     | 8.6        |
| SQ fat                     | 90     | 233 ± 13  | 32      | 572     | 17.9       |
| **Insulin sensitivity**    |        |           |         |         |            |
| \( S_{\text{ICLAMP}} \)    | 90     | 33.5 ± 1.6| 5.9     | 75.9    | 12.9       |
| \( S_{\text{IVGTT}} \)     | 36     | 4.5 ± 0.4 | 1.1     | 10.2    | 9.1        |
| **Glucose-stimulated insulin response** | | | | | |
| AIR\(_{\text{GLU}}\)        | 36     | 609 ± 38  | 217     | 1213    | 5.6        |
| SLOPE\(_{\text{INS}}\)      | 86     | 1.14 ± 0.13| 0.17   | 8.03    | 46.1       |
| **Insulin clearance**       |        |           |         |         |            |
| MCR\(_{\text{clamp}}\)      | 90     | 20.5 ± 0.5| 10.8    | 36.1    | 3.3        |
| FCR\(_{\text{IV}}\)         | 36     | 0.50 ± 0.05| 0.15   | 1.72    | 11.5       |
| MCR\(_{\text{IV}}\)         | 36     | 28.4 ± 1.7| 9.8     | 49.1    | 5.0        |

**FIGURE 1** Variability in adiposity and body weight in normal dogs. (A) Dogs ranked by total adiposity (height of stacked bars), with respective visceral (solid) and subcutaneous (hatched) fat mass. (B) Body weight for dogs ranked by total fat. Note that variability of total and subcutaneous fat greatly exceeds that of body weight.
predict $S_{\text{CLAMP}}$. The insulin response to hyperglycaemia was quantified as the slope relating the glucose–insulin relationship from STEP clamps, as well as the acute insulin response to glucose injection from the IVGTT (AIRG; see METHODS). While these independently obtained measures were highly correlated with each other ($P = 0.0065$), neither index was significantly associated with $S_{\text{CLAMP}}$. However, the inverse relationship between AIRG and insulin sensitivity was detected when the small subset of animals (6 of 36 animals undergoing IVGTTs) with lowest glucose tolerance ($K_G < 2.0 \text{ min}^{-1}$) was excluded from analysis ($P = 0.043$).

In contrast, we observed a robust relationship between insulin clearance and clamp-derived $S_{\text{CLAMP}}$ (Figure 3A). These variables were positively associated, meaning that decreasing hormone clearance was predictive of insulin resistance. Of particular interest was the observation that while insulin levels are strongly associated with insulin sensitivity under baseline, overnight-fasted conditions, it is insulin clearance, not secretion that exerts the dominant influence on circulating hormone levels. This finding was independent of experimental procedures, as the observation was confirmed with IVGTT-derived measures of both sensitivity and clearance (Figure 3B; $P = 0.0016$). While $S_{\text{CLAMP}}$ was influenced by rate of insulin infusion ($39.78 \pm 2.23, 28.93 \pm 2.16$, and $23.65 \pm 3.54 \text{ dl/min per kg per } \mu\text{U/ml}$ for infusion rates of 0.75, 1.15, and 1.5 mU/min per kg, respectively), this dose effect did not alter our primary observation. There was a strong, highly significant linear relationship between clearance and $S_{\text{CLAMP}}$ at both the 0.75 and 1.15 mU/min per kg infusion rates. (Data from the 1.5 mU/min per kg infusion rate was also highly linear ($r = 0.78$), but relationship only approached significance due to small group size ($P = 0.067$; $n = 6$ animals).) Slopes defining the clearance-sensitivity relationship were not statistically different across insulin infusion rates ($P = 0.567$). Insulin clearance was also strongly linked to both peripheral and hepatic insulin sensitivity, which raises the possibility that modulation of clearance could result in improvements in tissue insulin resistance.

### Discussion

This study was undertaken to examine the metabolic factors which determine insulin sensitivity under baseline, overnight-fasted conditions, in the absence of dietary or pharmacologic intervention. Our data indicate that a primary determinant of baseline insulin sensitivity was the metabolic clearance rate of insulin. This finding was independent of experimental methodology, as the relationship was equally strong whether clamp- or IVGTT-based indices of sensitivity or metabolic clearance rate of insulin are examined. In fact, clearance was far more important for determining sensitivity than was $\beta$-cell sensitivity to glucose ($P < 0.00001$ for clearance vs. $P = 0.36$ and $P = 0.07$ for AIRg and insulin-glucose slope from STEP clamps, respectively).

In nondiabetic subjects, decrements of insulin sensitivity are associated with increased circulating insulinemia to compensate for reduced insulin action and act to maintain fasting glucose within a narrow range. Compensatory hyperinsulinemia has been thought to

---

**TABLE 3 Regression coefficients describing overall and group-dependent effects of adiposity on $S_{\text{CLAMP}}$**

| Study group | Coefficient | SE | $P$-value |
|------------|-------------|----|-----------|
| Total fat: overall effect, $P = 0.0003$ ($r = 0.51$) | | |
| Reference group | 5.983 | 0.360 | 0.000 |
| Group 2 | 0.098 | 0.365 | 0.789 |
| Group 3 | −0.567 | 0.524 | 0.282 |
| Group 4 | 0.966 | 0.361 | 0.009 |
| Group 5 | 1.641 | 0.471 | 0.001 |
| Group 6 | 1.259 | 0.407 | 0.003 |
| Effect of total fat | −0.0014 | 0.0006 | 0.012 |
| Visceral fat: overall effect, $P = 0.0004$ ($r = 0.50$) | | |
| Reference group | 6.801 | 0.671 | 0.000 |
| Group 2 | 0.303 | 0.392 | 0.441 |
| Group 3 | −0.449 | 0.525 | 0.395 |
| Group 4 | 1.102 | 0.389 | 0.006 |
| Group 5 | 1.766 | 0.482 | 0.000 |
| Group 6 | 1.505 | 0.436 | 0.001 |
| Effect of visceral fat | −0.0955 | 0.0391 | 0.017 |
| Subcutaneous fat: overall effect, $P = 0.0006$ ($r = 0.49$) | | |
| Reference group | 6.277 | 0.502 | 0.000 |
| Group 2 | −0.094 | 0.363 | 0.797 |
| Group 3 | −0.651 | 0.532 | 0.225 |
| Group 4 | 0.788 | 0.346 | 0.029 |
| Group 5 | 1.545 | 0.471 | 0.002 |
| Group 6 | 1.044 | 0.407 | 0.012 |
| Effect of subcutaneous fat | −0.0699 | 0.0307 | 0.025 |

Pooled data set was comprised of individual studies performed by authors. Statistical analysis was performed to determine overall effect or effects of each individual study groups, defined as follows: Reference group (5), Group 2 (11), Group 3 (6), Group 4 (9), Group 5 (7), Group 6 (12). Statistics were not appreciably altered by choice of reference group. *Measures of $S_{\text{CLAMP}}$ and adiposity were normalized by square root transformation prior to statistical analysis (see Methods).*
result from upregulation of pancreatic \(\beta\)-cells, and elevated insulin secretion is often reported in insulin resistant states (4). However, once secreted, insulin enters the portal vein and hepatic circulation, where at least 50% of the hormone is extracted and metabolized, and the remainder enters the systemic circulation (20). If liver clearance of insulin is reduced, at the same level of insulin secretion, peripheral insulin concentrations will increase. Thus, fasting hyperinsulinemia during insulin resistance can result from increased secretion of insulin, but also from decreased hormone clearance. Indeed, prospective studies of the physiologic response to diet-induced fat feeding reveal that changes in both secretion and clearance contribute to compensatory hyperinsulinemia in dogs (3) and humans (4). This study demonstrates that insulin clearance may be dominant under baseline, unchallenged conditions as well.

To examine the predictors of insulin sensitivity in a sample of healthy animals, it is necessary that a sufficiently wide range of sensitivity is represented to ensure adequate power to detect key relationships. In this study, the primary measure of insulin sensitivity was obtained from hyperinsulinemic euglycemic clamps. Whole-body insulin sensitivity averaged 33.5 dl/min per kg per \(\mu\)U/ml, but exhibited nearly a 13-fold range from the most insulin resistant animal (SICLAMP = 5.9) to the most sensitive animal (SICLAMP = 75.9 dl/min per kg per \(\mu\)U/ml). Despite this range, dogs had normal fasting glucose held within a very narrow range (Table 2). These data are consistent with prior reports of a large range of clamp-derived \(M\) values across subjects with normal glucose tolerance (2).

Since obesity is often associated with insulin resistance, we examined the relationship between insulin sensitivity and body composition in our study sample. Despite relatively uniform body weight, dogs exhibited a strikingly wide range of adiposity (Figure 1). Variability was largely driven by subcutaneous fat mass, rather than adiposity within the visceral depot. Despite comparable body weight, subcutaneous fat mass exhibited a striking ~18-fold range across animals, whereas visceral adipose tissue mass varied over half that range (8.6-fold; Table 2). Further, visceral fat mass exhibited a tendency for a more limited capacity for expansion across the wide range of total adiposity, such that fat within the visceral cavity demonstrates a quasi-saturation as total fat deposition increases.

While it is generally believed that obesity is inversely proportional to insulin sensitivity, there is substantial variability in the relationship such that subjects with identical adiposity may exhibit vastly different degrees of sensitivity (21). Despite high degree of variability in both adiposity and insulin sensitivity, we observed a strong negative relationship between these factors in this study. Total trunk adipose tissue mass was strongly correlated with SICLAMP (\(P = 0.012\)), and was similarly strong for discrete adipose tissue mass within the visceral and subcutaneous depots, although these relationships were not apparent in several of the studies used in the present pooled analysis (Table 3). It is also possible that other adipose depots not measured in this study may have stronger influence on insulin sensitivity. It has been proposed that ectopic fat, particularly within the liver, may be the primary driver of obesity-linked insulin resistance (22), and in the absence of increased hepatic fat, elevation of whole body adiposity is not accompanied by insulin resistance (23). This relationship between hepatic fat and insulin sensitivity may also be mediated by insulin clearance, as liver fat is inversely correlated with insulin clearance in diabetic and nondiabetic subjects (24). Such a relationship was not observed in the canine model. Diet-induced obesity induced only modest accumulation of hepatic triglycerides, and hepatic lipid levels were not correlated with direct measures of insulin clearance (25), although in the larger canine cohort described herein, visceral adiposity measured by MRI was negatively associated with clearance. Adipose tissue within the omentum has also been implicated in the development of insulin resistance, and removal of omental fat, representing a small fraction of total fat mass, has marked effects to improve insulin sensitivity in lean animals (26), although this effect was not observed in subjects with morbid obesity (BMI > 40 kg/m\(^2\)) undergoing gastric bypass (27).

What mechanism could explain the relationship between metabolic clearance of insulin and insulin sensitivity? Insulin is cleared from the circulation by many organs, including liver, kidney, adipose tissue, and muscle, but the primary site of hormone clearance is in the liver (28). It is possible that the tissues into which insulin is cleared may be different between the two experimental methods used to quantify the process. During clamps, hyperinsulinemia is sustained for the experimental duration, and insulin-mediated vasodilation (29)
may allow greater recruitment of extrahepatic tissues for insulin clearance than may occur during the transient hyperinsulinemia characteristic of the IVGTT. Elevated nocturnal (not fasting) FFA levels have been reported during diet-induced insulin resistance in dogs (7) and may mediate compensatory changes in both β-cell function and insulin clearance. It is plausible that changes in insulin clearance will alter circulating insulin concentrations over the course of the day, which in turn could affect insulin-sensitive tissues such as skeletal muscle, thus suppressing peripheral insulin action.

There is supportive evidence of each component of this hypothesis. Diminished clearance of insulin increases systemic insulin levels (3,4). Hyperinsulinemia induced by exogenous infusion (30) or end-to-side portocaval shunt (31) impairs insulin-stimulated glucose uptake (30). Conversely, subjects with insulinomas who are treated with diazoxide exhibit reduction of hyperinsulinemia secondary to increased insulin clearance, and improved insulin sensitivity (30). The interplay between insulin clearance, circulating insulin, and insulin sensitivity is further supported by studies in transgenic mice with altered expression of CEACAM1, the key regulator of hepatic insulin clearance (32). Mice with liver-specific overexpression of the dominant-negative mutant of CEACAM1 exhibited decreased clearance, with resulting hyperinsulinemia, and animals exhibit marked insulin resistance. Hepatic steatosis has also been reported in mice with liver-specific inactivation of CEACAM1 (33). We have demonstrated prospective changes in CEACAM1 gene expression that track changes in clearance with diet-induced obesity in dogs (34). Insulin clearance is also modulated by insulin degrading enzyme (IDE), a ubiquitous molecule which mediates clearance of insulin and other proteins, including cerebral amyloid β-peptide, from the circulation (35). It is unclear whether IDE activity is altered in states of insulin resistance. Overall, these data are consistent with the hypothesis that insulin clearance is the primary determinant of insulin sensitivity by mediating circulating 24-hr insulin levels, which feed back to regulate peripheral insulin sensitivity. This scenario provides a mechanistic framework by which hepatic insulin clearance is linked to insulin sensitivity.

The question of whether changes in insulin clearance are a determinant of, or a result from, fluctuations in insulin action is difficult to definitively answer from our results. Indeed, we have previously reported a correlation between insulin clearance and sensitivity in a cross-sectional examination of nondiabetic Mexican-American subjects (36), and proposed that changes in clearance contribute to hyperinsulinemic compensation for insulin resistance. However, this prior study was small (n = 21), and clearance estimates were indirect and based on suboptimal measures of insulin secretion using nonspecific hormone assays. This study is large (n = 90 animals), and both insulin sensitivity and clearance were measured from independent experimental protocols (IVGTT and clamp) in nondiabetic animals that displayed a broad range of sensitivity. These robust data are consistent with an alternative proposal that changes in clearance precede those of insulin action. Future studies are underway to test this proposal through manipulation of insulin clearance in vivo.

In conclusion, we report that insulin clearance is likely the primary determinant of insulin sensitivity under baseline, overnight-fasted conditions in healthy dogs. Clearance was measured by two independent methodologies from both steady-state and dynamic experimental procedures. Among healthy animals of similar body weight and normal fasting glucose, both insulin sensitivity and body adiposity exhibited substantial variability, which were negatively correlated with one another. Of greater magnitude was the strong, positive relationship between insulin clearance and whole body insulin sensitivity. From these results, we propose the hypothesis whereby changes in insulin clearance result in insulin levels that feed back onto insulin action of peripheral and hepatic tissues. Taken together, these data support a central role for insulin clearance in the regulation of insulin sensitivity. It remains to be determined whether reduction in insulin clearance per se could be exploited in human subjects as an approach to enhance insulin sensitivity in insulin resistant individuals at risk for Type 2 diabetes.

Acknowledgments

Authors offer their sincere gratitude to Ed Zuniga and Edgard Parades for their gentle care and treatment of the experimental animals and to Dr. Erlinda Kirkman for her expert veterinary care and advice.

© 2013 The Obesity Society

References

1. Watanabe RM. The genetics of insulin resistance: where’s Waldo? Curr Diab Rep 2010;10:476-484.
2. Hollenbeck C, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 1987; 64:1169-1173.
3. Mittelman SD, van Citters GW, Kim SP, Davis DA, Dea MK, Bergman RN. The longitudinal compensation for fat induced insulin resistance includes reduced insulin clearance and enhanced B-cell response. Diabetes 2000;49:2116-2125.
4. Erdmann J, Kallabis B, Oppel U, Sypchenko O, Wagenpfeil S, Schusdziarra V. Development of hyperinsulinemia and insulin resistance during the early stage of weight gain. Am J Physiol 2008;294:E568-E575.
5. Ader M, Kim SP, Catalanlo KC, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005;54:862-871.
6. Kim SP, Ellmerer M, van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric, moderate fat diet in the dog. Diabetes 2003;52:2453-2460.
7. Kim SP, Catalanlo KJ, Hsu IR, Chui JD, Richey JM, Bergman RN. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia. Am J Physiol 2007;292:E1590-E1598.
8. Richey JM, Woolcott OO, Stefanovski D, et al. Rimonabant prevents additional accumulation of visceral and subcutaneous fat induced by high-fat diet in dogs. Am J Physiol 2009;296:E1311-E1318.
9. Kim SP, Woolcott OO, Hsu IR, et al. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs. Am J Physiol 2012;302:E1261-E1268.
10. Richey JM, Woolcott O, Stefanovski D, et al. Maintenance of normal beta-cell function during treatment with rimonabant. Diabetes 2008;57:A169 (abstract).
11. Diittmann J, Stefanovski D, Yae S, Ader M. Olanzapine-induced weight gain is independent of increased caloric intake in obese dogs. Obesity 2009;17:S250 (abstract).
12. Ionut V, Liu H, Mooradian V, et al. Novel canine models of obese prediabetes and mild type 2 diabetes. Am J Physiol 2010;298:E8-E48.
13. Somogyi M. Determination of blood sugar. J Biol Chem 1945;160:69-73.
14. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987;79:790-800.
15. Bradley DC, Steil GM, Bergman RN. Quantitation of measurement error with optimal segments: basis for adaptive time course smoothing. Am J Physiol 1993; 264:E902-E911.
16. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps: comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 1987;36:914-924.
17. Bostom BC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Therapeut 2003;5:1003-1015.
18. Mari A. Assessment of insulin sensitivity and secretion with the labeled intravenous glucose tolerance test: improved modeling analysis. Diabetologia 1998;41:1029-1039.
19. Efendic S, Weingot A, Cerasi E, Luft R. Insulin release, insulin sensitivity, and glucose intolerance. Proc Natl Acad Sci 1980;77:7425-7429.
20. Rebrin K, Steil GM, Getty L, Bergman RN. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995;44:1038-1045.
21. Lillioja S, Bogardus C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diab Metab Rev 1988;5:517-540.
22. Szendroedi J, Roden M. Ectopic lipids and organ function. Curr Opin Lipidol 2009; 20:50-56.
23. Magnkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity 2010;18:1510-1515.
24. Kotronen A, Juuriinen L, Tiikkaen M, Vehkavaaa S, Yki-Jarvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 2008;135:122-130.
25. Kim SP, Ellmerer M, Kirkman EL, Bergman RN. Beta-cell “rest” accompanies reduced first-pass hepatic insulin extraction in the insulin resistant, fat-fed canine model. Am J Physiol 2007;292:1581-1589.
26. Lottati M, Kolka CM, Stefanovski D, Kirkman EL, Bergman RN. Greater omentectomy improves insulin sensitivity in nonobese dogs. Obesity 2009;17:674-680.
27. Fabbrini E, Tamboli RA, Magnkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 2010;139:448-455.
28. Valeta-Mora ME, Scarfone A, Calvani M, Greco AV, Mingrone G. Insulin clearance in obesity. J Am Coll Nutr 2003;22:487-493.
29. Baron AD. Hemodynamic actions of insulin. Am J Physiol 1994;267:E187-E202.
30. Rizza RA, Mandarino LJ, Genest J, Baker BA, Gerich JE. Production of insulin resistance by hyperinsulinemia in man. Diabetologia 1985;28:70-75.
31. Minossi JG, Mercadante MC, Scellini SA, Brandao-Neto J, Spadella CT. Experimental pancreas transplantation: the consequences of portocaval shunt on blood glucose, plasma insulin, and glucagon. Transplant Proc 1998;30:624-626.
32. Poy MN, Yang Y, Rezaei K, et al. CEACAM1 regulates insulin clearance in liver. Nature Gen 2002;30:270-276.
33. Lee SJ, Heinrich G, Fedorova L, et al. Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice. Gastroenterology 2008;135:2084-2095.
34. Kabir M, Iyer M, Stefanovski D, et al. Reduced hepatic insulin clearance as measured by CEACAM-1 expression accounts for hyperinsulinemia in fat fed dogs. Diabetes 2011;60:1694-P (abstract).
35. Fernandez-Gamba A, Leal MC, Morelli L, Castano EM. Insulin-degrading enzyme: structure-function relationship and its possible role in health and disease. Curr Pharm Des 2009;15:3644-3655.
36. Haffner SM, Stern MP, Watanabe RM, Bergman RN. Relationship of insulin clearance and secretion to insulin sensitivity in non-diabetic Mexican Americans. Eur J Clin Invest 1992;22:147-153.